Price T Rowe Associates Inc Immuneering Corp Transaction History
Price T Rowe Associates Inc
- $812 Billion
- Q1 2025
A detailed history of Price T Rowe Associates Inc transactions in Immuneering Corp stock. As of the latest transaction made, Price T Rowe Associates Inc holds 659,009 shares of IMRX stock, worth $995,103. This represents 0.0% of its overall portfolio holdings.
Number of Shares
659,009
Previous 767,124
14.09%
Holding current value
$995,103
Previous $1.69 Million
40.64%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding IMRX
# of Institutions
37Shares Held
4.78MCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA1.06MShares$1.6 Million0.0% of portfolio
-
Marshall Wace, LLP London, X0808KShares$1.22 Million0.0% of portfolio
-
Black Rock Inc. New York, NY533KShares$805,3790.0% of portfolio
-
Morgan Stanley New York, NY467KShares$705,5110.0% of portfolio
-
Southport Management, L.L.C. Wilson, WY245KShares$369,9501.61% of portfolio
About Immuneering Corp
- Ticker IMRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,392,300
- Market Cap $39.9M
- Description
- Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to tr...